Consultation on the Prescription Drug List: Hyoscine butylbromide

The purpose of this Notice of Consultation is to provide an opportunity to comment on the proposal to switch injectable Hyoscine butylbromide to prescription status from ethical status for human use by adding it to the Human Prescription Drug List (PDL). Injectable Hyoscine butylbromide is already listed on the Veterinary Prescription Drug List.

A question-and-answer document has also been created to explain some of the changes to the new Prescription Drug List and the administrative process for assigning prescription status.

How to Get Involved

This consultation is open for comment until December 30, 2015. Please read through the information provided in the link below titled "Consultation Document". Once read, please submit your comments via email, facsimile or by mail to:

• Health Canada
  Prescription Drug Status Committee
  Address Locator 3102C3
  Holland Cross, Tower B
  1600 Scott Street
  Ottawa, Ontario
  K1A 0K9
• Telephone: 613-957-1058
  Facsimile: 613-941-5035
  E-mail: drug_prescription_status-statut_d'ordonnance_des_drogues@hc-sc.gc.ca

Consultation Document

Interested parties are encouraged to provide comments and suggestions by December 30, 2015.

Reporting to Canadians

The results of the consultation will be made available on this website.

If you have any questions, contact us the Prescription Drug Status Committee.